Drug Profile
OPC 1
Alternative Names: AST-OPC1; GRNOPC 1; hESC-derived oligodendrocyte progenitor cells (OPC) - Geron/University of California; Oligodendrocyte progenitor cells - Lineage Cell Therapeutics; OPC-1Latest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Geron Corporation
- Developer Asterias Biotherapeutics; Lineage Cell Therapeutics
- Class Neural stem cell therapies; Pluripotent stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Spinal cord injuries
- No development reported Multiple sclerosis; Stroke
- Discontinued Alzheimer's disease; Canavan disease
Most Recent Events
- 13 Feb 2024 Lineage Cell Therapeutics plans a DOSED clinical trial for Spinal cord injuries in Q2 of 2024
- 18 Dec 2023 Lineage Cell Therapeutics files an IND amendment application with the US FDA in the US for subacute and chronic Spinal cord injury
- 11 Aug 2023 Lineage Cell Therapeutics received Type B meeting response from US FDA